Rockefeller Capital Management’s Arbutus Biopharma ABUS Stock Holding History

Rockefeller Capital Management’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$299K	Sell	62,500 -500	-0.8%	-$2.41K	﹤0.01%	2439
2026 Q2	$302K	Hold	63,000	–	–	﹤0.01%	2372
2026 Q1	$284K	Hold	63,000	–	–	﹤0.01%	2288
2025 Q4	$303K	Hold	63,000	–	–	﹤0.01%	2154
2025 Q3	$286K	Buy	+63,000	New	+$231K	﹤0.01%	2044
2025 Q2	–	Sell	-63,000	Closed	-$220K	–	1715
2025 Q1	$220K	Sell	63,000 -43,615	-41%	-$145K	﹤0.01%	1643
2024 Q4	$349K	Buy	106,615 +43,615	+69%	+$160K	﹤0.01%	1570
2024 Q3	$243K	Buy	+63,000	New	+$242K	﹤0.01%	1576

Other funds holding ABUS

Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

Los Angeles Capital Management Los Angeles, California $29.2B AUM 33.64% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $83.6B AUM 19.78% 1-Year Est. Return

Rockefeller Capital Management's ABUS Position: Q3 2026 in Review

Rockefeller Capital Management reduced its Arbutus Biopharma (ABUS) stake by 0.79% in Q3 2026, selling an estimated $2.41K and leaving 62,500 shares worth $299K. The position accounts for ﹤0.01% of the portfolio, ranked #2439.

Rockefeller Capital Management first reported a position in ABUS in Q3 2024 and has held it in 8 quarters since. The position peaked at $349K in Q4 2024. 145 funds tracked by Wall St. Rank hold ABUS as of Q3 2026.

Rockefeller Capital Management held 62,500 shares of Arbutus Biopharma worth $299K as of Q3 2026.
Rockefeller Capital Management sold 500 Arbutus Biopharma shares in Q3 2026, an estimated $2.41K.
Arbutus Biopharma made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q3 2026, its #2439 holding.
Rockefeller Capital Management first reported a position in Arbutus Biopharma in Q3 2024 and has held it in 8 quarters since.
Rockefeller Capital Management's Arbutus Biopharma position peaked at $349K in Q4 2024.
145 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q3 2026.

Based on Rockefeller Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.